Efficacy of Low-Dose Hydrochlorothiazide in Combination with Telmisartan on Early Morning Blood Pressure in Uncontrolled Hypertensive Patients

References

• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981–97
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003; 289: 2560–2572
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology, Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105–1187
   PubMed Web of Science ®Google Scholar
• Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res. 2006; 29: 143–151
   PubMed Web of Science ®Google Scholar
• MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med. 1996; 156: 278–285
   PubMed Web of Science ®Google Scholar
• Fenton C, Keating GM, Scott LJ. Telmisartan/hydrochlorothiazide: In the treatment of essential hypertension. Drugs. 2003; 63: 2013–2026
   PubMed Web of Science ®Google Scholar
• Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999; 34: 144–150
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000; 283: 2404–2410
   PubMed Web of Science ®Google Scholar
• Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J. STAR Investigators Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006; 29: 2592–2597
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator–activated receptor-γ activity. Circulation. 2004; 109: 2054–2057
   PubMed Web of Science ®Google Scholar
• Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension. 2004; 43: 993–1002
   PubMed Web of Science ®Google Scholar
• Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: Metabolic and antiatherogenic consequences. Diabetes Care. 2005; 28: 757–758
   PubMed Web of Science ®Google Scholar
• Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005; 4: 6
   PubMed Web of Science ®Google Scholar
• Nagel JM, Tietz AB, Goke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism. 2006; 55: 1149–1154
   PubMed Web of Science ®Google Scholar
• Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Mass R, Schulze F, Silberhorn E, Böger RH. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism. 2006; 55: 1159–1164
   PubMed Web of Science ®Google Scholar
• Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004; 27: 457–464
   PubMed Web of Science ®Google Scholar
• Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004; 291: 1342–1349
   PubMed Web of Science ®Google Scholar
• Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Kikuya M, Ito S, Satoh H, Hisamichi S. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens. 1998; 16: 971–975
   PubMed Web of Science ®Google Scholar
• Imai Y, Otsuka K, Kawano Y, Shimada K, Hayashi H, Tochikubo O, Miyakawa M, Fukiyama K. Japanese Society of Hypertension. Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res. 2003; 26: 771–782
   PubMed Web of Science ®Google Scholar
• Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation. 2003; 107: 1401–1406
   PubMed Web of Science ®Google Scholar
• Neutel JM, Littlejohn TW, Chrysant SG, Singh A, on behalf of the Telmisartan Study Group. Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res. 2005; 28: 555–563
   PubMed Web of Science ®Google Scholar
• Uzu T, Kimur G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1999; 100: 1635–1638
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit. 2004; 9: 203–210
   PubMed Web of Science ®Google Scholar
• Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res 2003; 26: 521–525
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033–1041
   PubMed Web of Science ®Google Scholar
• Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, Applegate WB. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens. 2000; 18: 1149–1154
   PubMed Web of Science ®Google Scholar
• Kau ST. Diuretics: What we have and what we needed. Prog Pharmacol. 1988; 6: 1–63
   Google Scholar
• Steele TN. Importance and pathogenesis of diuretic-induced hyperuricemia. Diuretics IV: Chemistry, Pharmacology and Clinical Applications, JB Puschett, A Greenberg. Elsevier Science, Amsterdam 1993; 231–238
   Google Scholar
• Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002; 417: 447–452
   PubMed Web of Science ®Google Scholar
• Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320: 211–217
   PubMed Web of Science ®Google Scholar
• Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens. 1993; 6: 28–32
   PubMed Web of Science ®Google Scholar
• Rayner BL, Trinder YA, Baines D, Isaacs S, Opie LH. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens. 2006; 19: 208–213
   PubMed Web of Science ®Google Scholar
• Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG, Parks JH, Coe FL. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. 1999; 56: 1879–1885
   PubMed Web of Science ®Google Scholar
• Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992; 42: 333–335
   PubMed Web of Science ®Google Scholar
• Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med. 1996; 101: 71S–82S
   PubMedGoogle Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ. 2003; 326: 1427
   PubMed Web of Science ®Google Scholar